Janthinobacterium lividum
Cell therapyexperimental
Janthinobacterium lividum is an aerobic, Gram-negative, soil-dwelling bacterium that has a distinctive dark-violet color, due to a compound called violacein, which is produced when glycerol is metabolized as a carbon source. Violacein has antibacterial, antiviral, and antifungal properties. Its antifungal properties are of particular interest, since J. lividum is found on the skin of certain amphibians, including the red-backed salamander, where it prevents infection by the devastating chytrid fungus. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 19, 2019 (NCT04152226)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaJanthinobacterium lividum ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04192513 | Phase 2 | May 20, 2019 | DermBiont, Inc., Instituto Dermatologico y Cirugia de Piel |
| NCT04152226 | Phase 2 | Feb 19, 2019 | DermBiont, Inc., Instituto Dermatologico y Cirugia de Piel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DermBiont, Inc. | For profit | 2 | 2 | 1 | 2019 |
| Instituto Dermatologico y Cirugia de Piel | Academic/Hospital | 2 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1